Despite Promising Laboratory Data Bone Cancer Treatment Ineffective
Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults. Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases the levels of a certain key protein in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma cell lines in the laboratory. Treatment of Ewing sarcoma that relapses is difficult.
Original post by Allergy News From Medical News Today
Related Articles
Promising Data On Head And Neck Cancer Announced By DNAR At 2008 American Society Of Clinical Oncology Meeting
ImmunoCellular Therapeutics Reports Additional Data From Promising Brain Cancer Clinical Trial
DHEA Hormone Replacement Increases Bone Density In Older Women
Bone Cancer Research Trust Calls For New Treatments For Bone Cancer
Callisto Pharmaceuticals Reports Promising Interim Phase II Data For Atiprimod In Advanced Carcinoid Cancer
Promising Data On Head And Neck Cancer Announced By DNAR At 2008 American Society Of Clinical Oncology Meeting
ImmunoCellular Therapeutics Reports Additional Data From Promising Brain Cancer Clinical Trial
DHEA Hormone Replacement Increases Bone Density In Older Women
Bone Cancer Research Trust Calls For New Treatments For Bone Cancer
Callisto Pharmaceuticals Reports Promising Interim Phase II Data For Atiprimod In Advanced Carcinoid Cancer